Cytotoxic activity of gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia correlates with the expression of protein kinase Syk

Leukemia

Volumn 20, Issue 12, 2006, Pages 2093-2101

  Balaian, L ^a   Ball, E D ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; CD33 ANTIGEN; GEMTUZUMAB OZOGAMICIN; PROTEIN KINASE SYK; SMALL INTERFERING RNA;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DRUG RESPONSE; DRUG SENSITIVITY; HUMAN; HUMAN CELL; LEUKEMIA CELL; NUCLEOTIDE SEQUENCE; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

EID: 33751227854     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404437     Document Type: Article

References (42)

1. Griffin JD, Linch D, Sabbath K, Larcom P, Schlossman SF. A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. Leukemia Res 1984; 8: 521-527.
2. Sievers EL, Appelbaum FR, Spielberger RT. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: A phase I study of an anti-CD33 calicheamycin immunoconjugate. Blood 1999; 93: 3678-3684.
3. Freeman SD, Kelm S, Barber EK, Crocker PR. Characterization of CD33 as a new member of the sialoadhesin family of cellular interaction molecules. Blood 1995; 85: 2005-2012.
4. Ulyanova T, Blasioli J, Woodford-Thomas TA, Thomas ML. The sialoadhesin CD33 is a myeloid-specific inhibitory receptor. Eur J Immunol 1999; 29: 3440-3449.
5. Taylor VC, Buckley CD, Douglas M, Cody AJ, Simmons DL, Freeman SD. The myeloid-specific scialic acid-binding receptor, CD33, associates with the protein tyrosine phosphatases, SHP-1 and SHP-2. J Biol Chem 1999; 274: 11505-11512.
6. Paul SP, Taylor LS, Sansbury EK, McVicar DW. Myeloid specific human CD33 is an inhibitory receptor with differential ITIM function in recruiting the phosphatases SHP-1 and SHP-2. Blood 2000; 96: 483-490.
7. Vitale C, Romagnani C, Falco M, Ponte M, Mingari MC. Engagement of p75/ AIRM1 or CD33 inhibits the proliferation of normal or leukemic myeloid cells. Proc Natl Acad Sci USA 1999; 96: 15091-15096.
8. Vitale C, Romagnani C, Puccetti A, Olive D, Mingari MC. Surface expression and function of p75/AIRM-1 or CD33 in acute myeloid leukemias: Engagement of CD33 induces apoptosis of leukemic cells. Proc Natl Acad Sci USA 2001; 98: 5764-5769.
9. Mingari MC, Vitale C, Romagnani C, Falco M, Moretta L. p75/AIRM1 and CD33, two sialoadhesin receptors that regulate the proliferation or the survival of normal and leukemic myeloid cells. Immunol Rev 2001; 181: 260-268.
10. Bae J, Martinson JA, Klingemann HG. Heteroclitic CD33 peptide with enhanced anti-acute myeloid leukemic immunogenicity. Clin Cancer Res 2004; 10: 7043-7052.
11. Sievers EL. Targeted therapy of acute myeloid leukemia with monoclonal antibodies and immunoconjugates. Cancer Chemother Pharmacol 2000; 46: 18-22.
12. Qin S, Yamamura H. Up-regulation of Syk activity during HL60 cell differentiation into granulocyte but not into monocyte/ macrophage-lineage. Biochem Biophys Res Commun 1997; 236: 697-701.
13. Tsubokawa M, Tohyama Y, Tohyama K, Asahi M, Inazu T, Nakamura H et al. Interleukin-3 activates Syk in a human myeloblastic leukemia cell line, AML-193. Eur J Biochem 1997; 249: 792-796.
14. Raeder EM, Mansfield PJ, Hinkovska-Galcheva V, Shayman JA, Boxer LA. Syk activation initiates downstream signaling events during human polymorphonuclear leukocyte phagocytosis. J Immunol 1999; 163: 6785-6793.
15. Cambien B, Pomeranz M, Millet MA, Rossi B, Schmid-Alliana A. Signal transduction involved in MCP-1-mediated monocytic trans-endothelian migration. Blood 2001; 97: 359-366.
16. Nakashima K, Kokubo T, Shichijo M, Li YF, Yura T, Yamamoto N. A novel Syk kinase-selective inhibitor blocks antigen presentation of immune complexes in dendritic cells. Eur J Pharmacol 2004; 505: 223-228.
17. Shen L, Lang ML, Wade WF. The ins and outs of getting in: Structures and signals that enhance BCR or Fc receptor-mediated antigen presentation. Immunopharmacology 2000; 49: 227-240.
18. Dustin LB, Plas DR, Wong J, Hu YT, Soto C, Chan AC et al. Expression of dominant-negative src-homology domain 2-containing protein tyrosine phosphatase -1 results in increased Syk tyrosine kinase activity and B cell activation. J Immunol 1999; 162: 2717-2724.
19. Kraft S, Katoh N, Novak N, Koch S, Bieber T. Unexpected functions of FcepsilonRI on antigen-presenting cells. Int Arch Allergy Immunol 2001; 124: 35-37.
20. Hamawy MM, Fischler C, Zhang J, Siraganian RP. Fc epsilon RI aggregation induces tyrosine phosphorylation of a novel 72 kDa protein downstream of Syk. Biochem Biophys Res Commun 1997; 239: 670-675.
21. Xu R, Seger R, Pecht I. Cutting edge: Extracellular signal-regulated kinase activates syk: A new potential feedback regulation of Fc epsilon receptor signaling. J Immunol 1999; 163: 1110-1114.
22. Ma H, Yankee TM, Hu J, Asai DJ, Harrison ML, Geahlen RL. Visualization of Syk-antigen receptor interactions using green fluorescent protein: differential roles for Syk and Lyn in the regulation of receptor capping and internalization. J Immunol 2001; 166: 1507-1516.
23. Ebel C, Schmidt RE, Hundt M. Signal transduction via both human low-affinity IgG Fc receptors, Fc gamma RIIa and Fc gamma RIIIb, depends on the activity of different families of intracellular kinases. Immunobiology 2001; 203: 616-628.
24. Law CL, Sidorenko SP, Chandran KA, Zhao Z, Shen SH, Fischer EH et al. CD22 associates with protein tyrosine phosphatase 1C, Syk and phospholipase C-gamma 1 upon B cell activation. J Exp Med 1996; 183: 547-560.
25. Tuscano JM, Engel P, Tedder TF, Agarval A, Kehrl JH. Involvement of p72syk kinase, p53/56lyn kinase and phosphatidyl inositol-3 kinase in signal transduction via the human B lymphocyte antigen CD22. Eur J Immunol 1996; 26: 1246-1252.
26. Yohannan J, Wienands J, Coggeshall KM, Justement LB. Analysis of tyrosine phosphorylation-dependent interactions between stimulatory effector proteins and the B cell co-receptor CD22. J Biol Chem 1999; 274: 18769-18776.
27. Otipoby KL, Draves KE, Clark EA. CD22 regulates B cell receptor-mediated signals via two domains that independently recruit Grb2 and SHP-1. J Biol Chem 2001; 276: 44315-44322.
28. Balaian L, Ball ED. Direct effect of bispecific anti-CD33 x anti-CD64 antibody on proliferation and signaling in myeloid cells. Leukemia Res 2001; 25: 1115-1125.
29. Balaian L, Zhong RK, Ball ED. The inhibitory effect of anti-CD33 monoclonal antibodies on AML cells growth correlates with Syk and/or ZAP-70 expression. Exp Hematol 2003; 5: 363-371.
30. Goodman PA, Wood CM, Vassilev A, Mao C, Uckun FM. Spleen tyrosine kinase (Syk) deficiency in childhood pro-B cell acute lymphoblastic leukemia. Oncogene 2001; 20: 3969-3978.
31. Goodman PA, Burkhardt N, Juran B, Tibbles HE, Uckun FM. Hypermethylation of the spleen tyrosine kinase promoter in T-lineage acute lymphoblastic leukemia. Oncogene 2003; 22: 2504-2514.
32. Ushmorov A, Leithauser F, Sakk O, Weinhausel A, Popov S, Moller P et al. Epigenetic process play a major role in B-cell-specific gene silencing in classical Hodgkin lymphoma. Blood 2006; 107: 2493-2500.
33. Coopman PJ, Mueller SC. The Syk tyrosine kinase: A new negative regulator in tumor growth and progression. Cancer Lett 2006; 241: 159-173.
34. Stewart ZA, Pieterpol JA. Syk: A new player in the field of breast cancer. Breast Cancer Res 2001; 3: 5-7.
35. Coopman PJ, Do MT, Barth M, Bowden ET, Hayes AJ, Basyuk E et al. The Syk tyrosine kinase suppresses malignant growth of human breast cancer cells. Nature 2000; 406: 742-747.
36. Yuan Y, Mendez R, Sahin A, Dai JL. Hypermethylation leads to silencing of the SYK gene in human breast cancer. Cancer Res 2001; 61: 5558-5561.
37. Yuan Y, Liu H, Sahin A, Le Dai J. Reactivation of syk expression by inhibition of DNA methylation suppresses breast cancer cell invasiveness. Int J cancer 2005; 113: 654-659.
38. Jabbour EJ, Giles EJ. New agents in myelodysplastic syndromes. Curr Hematol Rep 2005; 4: 191-199.
39. Fenaux P. Inhibitors of DNA methylation: Beyond myelodysplastic syndromes. Natl Clin Pract Oncol 2005; 2: 836-844.
40. Claus L, Almstedt M, Lubbert M. Epigenetic treatment of hematopoietic malignancies: In vivo targets of demethylating agents. Semin Oncol 2005; 32: 511-520.
41. Balaian L, Ball ED. Anti-CD33 monoclonal antibodies enhance the cytotoxic effects of cytosine arabinoside and idarubicin on acute myeloid leukemia (AML) cells through similarities in their signaling pathways. Exp Hematol 2005; 33: 199-211.
42. Esteller M. DNA methylation and cancer therapy: New developments and expectations. Curr Opin Oncol 2005; 17: 55-60.